New B-cell CD molecules

Immunology Letters

Volumn 134, Issue 2, 2011, Pages 104-112

  Matesanz Isabel, Jessica ^a   Sintes, Jordi ^a   Llinàs, Laia ^a   de Salort, Jose ^a   Lázaro, Adriana ^a   Engel, Pablo ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

B cells; Cell surface receptors; FACS; HLDA9; Monoclonal antibodies

Indexed keywords

CD307A ANTIGEN; CD307B ANTIGEN; CD307C ANTIGEN; CD307D ANTIGEN; CD351 ANTIGEN; CD352 ANTIGEN; CD353 ANTIGEN; CD355 ANTIGEN; CD358 ANTIGEN; CD361 ANTIGEN; CD363 ANTIGEN; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR; HERPESVIRUS ENTRY MEDIATOR; INTERLEUKIN 10 RECEPTOR ALPHA; INTERLEUKIN 15 RECEPTOR ALPHA; INTERLEUKIN 21 RECEPTOR ALPHA; LEUKOCYTE ANTIGEN; LYMPHOCYTE ANTIGEN; MONOCLONAL ANTIBODY; SYNDECAN 2; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 1; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ANTIGEN STRUCTURE; ARTICLE; B LYMPHOCYTE ACTIVATION; B LYMPHOCYTE DIFFERENTIATION; CELL MATURATION; CELL SURFACE; CONTROLLED STUDY; FLOW CYTOMETRY; GERMINAL CENTER; GRANULOCYTE FUNCTION; GRANULOCYTE PRECURSOR; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKOCYTE ACTIVATION; LYMPHOCYTE SUBPOPULATION; MEMORY CELL; MOLECULAR DYNAMICS; MONOCYTE; NATURAL KILLER CELL; PLASMA CELL; PLASMACYTOID DENDRITIC CELL; PRE B LYMPHOCYTE; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; B-LYMPHOCYTES; BONE MARROW CELLS; HUMANS; IMMUNOGLOBULINS; MICE; PALATINE TONSIL; RECEPTORS, CYTOKINE; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 78650294948     PISSN: 01652478     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imlet.2010.09.019     Document Type: Article

References (85)

1. Lander E.S., Linton L.M., Birren B., Nusbaum C., Zody M.C., Baldwin J., et al. Initial sequencing and analysis of the human genome. Nature 2001, 409:860-921.
2. Chattopadhyay K., Lazar-Molnar E., Yan Q., Rubinstein R., Zhan C., Vigdorovich V., et al. Sequence, structure, function, immunity: structural genomics of costimulation. Immunol Rev 2009, 229:356-386.
3. Barclay A.N. Membrane proteins with immunoglobulin-like domains--a master superfamily of interaction molecules. Semin Immunol 2003, 15:215-223.
4. Davis R.S., Ehrhardt G.R., Leu C.M., Hirano M., Cooper M.D. An extended family of Fc receptor relatives. Eur J Immunol 2005, 35:674-680.
5. Davis R.S. Fc receptor-like molecules. Annu Rev Immunol 2007, 25:525-560.
6. Leu C.M., Davis R.S., Gartland L.A., Fine W.D., Cooper M.D. FcRH1: an activation coreceptor on human B cells. Blood 2005, 105:1121-1126.
7. Du X., Nagata S., Ise T., Stetler-Stevenson M., Pastan I. FCRL1 on chronic lymphocytic leukemia, hairy cell leukemia, and B-cell non-Hodgkin lymphoma as a target of immunotoxins. Blood 2008, 111:338-343.
8. Polson A.G., Zheng B., Elkins K., Chang W., Du C., Dowd P., et al. Expression pattern of the human FcRH/IRTA receptors in normal tissue and in B-chronic lymphocytic leukemia. Int Immunol 2006, 18:1363-1373.
9. Li F.J., Ding S., Pan J., Shakhmatov M.A., Kashentseva E., Wu J., et al. FCRL2 expression predicts IGHV mutation status and clinical progression in chronic lymphocytic leukemia. Blood 2008, 112:179-187.
10. Kochi Y., Yamada R., Suzuki A., Harley J.B., Shirasawa S., Sawada T., et al. A functional variant in FCRL3, encoding Fc receptor-like 3, is associated with rheumatoid arthritis and several autoimmunities. Nat Genet 2005, 37:478-485.
11. Swainson L.A., Mold J.E., Bajpai U.D., McCune J.M. Expression of the autoimmune susceptibility gene FcRL3 on human regulatory T cells is associated with dysfunction and high levels of programmed cell death-1. J Immunol 2010, 184:3639-3647.
12. Ehrhardt G.R., Davis R.S., Hsu J.T., Leu C.M., Ehrhardt A., Cooper M.D. The inhibitory potential of Fc receptor homolog 4 on memory B cells. Proc Natl Acad Sci U S A 2003, 100:13489-13494.
13. Ehrhardt G.R., Hsu J.T., Gartland L., Leu C.M., Zhang S., Davis R.S., et al. Expression of the immunoregulatory molecule FcRH4 defines a distinctive tissue-based population of memory B cells. J Exp Med 2005, 202:783-791.
14. Falini B., Tiacci E., Pucciarini A., Bigerna B., Kurth J., Hatzivassiliou G., et al. Expression of the IRTA1 receptor identifies intraepithelial and subepithelial marginal zone B cells of the mucosa-associated lymphoid tissue (MALT). Blood 2003, 102:3684-3692.
15. Daeron M. Fc receptor biology. Annu Rev Immunol 1997, 15:203-234.
16. Kikuno K., Kang D.W., Tahara K., Torii I., Kubagawa H.M., Ho K.J., et al. Unusual biochemical features and follicular dendritic cell expression of human Fcα/μ receptor. Eur J Immunol 2007, 37:3540-3550.
17. Yang L., Shen L., Shao Y., Zhao Q., Zhang W. Cytoplasmic domain of human Fcα/μ receptor is required for ligand internalization. Cell Immunol 2009, 258:78-82.
18. Shibuya A., Sakamoto N., Shimizu Y., Shibuya K., Osawa M., Hiroyama T., et al. Fc α/μ receptor mediates endocytosis of IgM-coated microbes. Nat Immunol 2000, 1:441-446.
19. Honda S., Kurita N., Miyamoto A., Cho Y., Usui K., Takeshita K., et al. Enhanced humoral immune responses against T-independent antigens in Fcα/μR-deficient mice. Proc Natl Acad Sci U S A 2009, 106:11230-11235.
20. Calpe S., Wang N., Romero X., Berger S.B., Lanyi A., Engel P., et al. The SLAM and SAP gene families control innate and adaptive immune responses. Adv Immunol 2008, 97:177-250.
21. Ma C.S., Nichols K.E., Tangye S.G. Regulation of cellular and humoral immune responses by the SLAM and SAP families of molecules. Annu Rev Immunol 2007, 25:337-379.
22. Engel P., Eck M.J., Terhorst C. The SAP and SLAM families in immune responses and X-linked lymphoproliferative disease. Nat Rev Immunol 2003, 3:813-821.
23. Detre C., Keszei M., Romero X., Tsokos G.C., Terhorst C. SLAM family receptors and the SLAM-associated protein (SAP) modulate T cell functions. Semin Immunopathol 2010, 32:157-171.
24. Bottino C., Falco M., Parolini S., Marcenaro E., Augugliaro R., Sivori S., et al. Gntb-A, a novel Sh2d1a-associated surface molecule contributing to the inability of natural killer cells to kill Epstein-Barr virus-infected B cells in X-linked lymphoproliferative disease. J Exp Med 2001, 194:235-246.
25. Flaig R.M., Stark S., Watzl C. Cutting edge: NTB-A activates NK cells via homophilic interaction. J Immunol 2004, 172:6524-6527.
26. Munitz A., Bachelet I., Fraenkel S., Katz G., Mandelboim O., Simon H.U., et al. 2B4 (CD244) is expressed and functional on human eosinophils. J Immunol 2005, 174:110-118.
27. Korver W., Singh S., Liu S., Zhao X., Yonkovich S., Sweeney A., et al. The lymphoid cell surface receptor NTB-A: a novel monoclonal antibody target for leukaemia and lymphoma therapeutics. Br J Haematol 2007, 137:307-318.
28. Kingsbury G.A., Feeney L.A., Nong Y., Calandra S.A., Murphy C.J., Corcoran J.M., et al. Cloning, expression, and function of BLAME, a novel member of the CD2 family. J Immunol 2001, 166:5675-5680.
29. Ford J.W., McVicar D.W. TREM and TREM-like receptors in inflammation and disease. Curr Opin Immunol 2009, 21:38-46.
30. Tessarz A.S., Cerwenka A. The TREM-1/DAP12 pathway. Immunol Lett 2008, 116:111-116.
31. Sharif O., Knapp S. From expression to signaling: roles of TREM-1 and TREM-2 in innate immunity and bacterial infection. Immunobiology 2008, 213:701-713.
32. Klesney-Tait J., Turnbull I.R., Colonna M. The TREM receptor family and signal integration. Nat Immunol 2006, 7:1266-1273.
33. Bouchon A., Facchetti F., Weigand M.A., Colonna M. TREM-1 amplifies inflammation and is a crucial mediator of septic shock. Nature 2001, 410:1103-1107.
34. Takai Y., Miyoshi J., Ikeda W., Ogita H. Nectins and nectin-like molecules: roles in contact inhibition of cell movement and proliferation. Nat Rev Mol Cell Biol 2008, 9:603-615.
35. Fuchs A., Colonna M. The role of NK cell recognition of nectin and nectin-like proteins in tumor immunosurveillance. Semin Cancer Biol 2006, 16:359-366.
36. Boles K.S., Barchet W., Diacovo T., Cella M., Colonna M. The tumor suppressor TSLC1/NECL-2 triggers NK-cell and CD8+ T-cell responses through the cell-surface receptor CRTAM. Blood 2005, 106:779-786.
37. Patino-Lopez G., Hevezi P., Lee J., Willhite D., Verge G.M., Lechner S.M., et al. Human class-I restricted T cell associated molecule is highly expressed in the cerebellum and is a marker for activated NKT and CD8+ T lymphocytes. J Neuroimmunol 2006, 171:145-155.
38. Collette Y., Gilles A., Pontarotti P., Olive D. A co-evolution perspective of the TNFSF and TNFRSF families in the immune system. Trends Immunol 2003, 24:387-394.
39. Zhang G. Tumor necrosis factor family ligand-receptor binding. Curr Opin Struct Biol 2004, 14:154-160.
40. Watts T.H. TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol 2005, 23:23-68.
41. del Rio M.L., Lucas C.L., Buhler L., Rayat G., Rodriguez-Barbosa J.I. HVEM/LIGHT/BTLA/CD160 cosignaling pathways as targets for immune regulation. J Leukoc Biol 2010, 87:223-235.
42. Gavrieli M., Sedy J., Nelson C.A., Murphy K.M. BTLA and HVEM cross talk regulates inhibition and costimulation. Adv Immunol 2006, 92:157-185.
43. Kwon B., Kim B.S., Cho H.R., Park J.E., Kwon B.S. Involvement of tumor necrosis factor receptor superfamily (TNFRSF) members in the pathogenesis of inflammatory diseases. Exp Mol Med 2003, 35:8-16.
44. Steinberg M.W., Shui J.W., Ware C.F., Kronenberg M. Regulating the mucosal immune system: the contrasting roles of LIGHT, HVEM, and their various partners. Semin Immunopathol 2009, 31:207-221.
45. Nocentini G., Riccardi C. GITR: a multifaceted regulator of immunity belonging to the tumor necrosis factor receptor superfamily. Eur J Immunol 2005, 35:1016-1022.
46. Nocentini G., Ronchetti S., Cuzzocrea S., Riccardi C. GITR/GITRL: more than an effector T cell co-stimulatory system. Eur J Immunol 2007, 37:1165-1169.
47. Ronchetti S., Nocentini G., Riccardi C., Pandolfi P.P. Role of GITR in activation response of T lymphocytes. Blood 2002, 100:350-352.
48. Tone M., Tone Y., Adams E., Yates S.F., Frewin M.R., Cobbold S.P., et al. Mouse glucocorticoid-induced tumor necrosis factor receptor ligand is costimulatory for T cells. Proc Natl Acad Sci U S A 2003, 100:15059-15064.
49. Pan G., Bauer J.H., Haridas V., Wang S., Liu D., Yu G., et al. Identification and functional characterization of DR6, a novel death domain-containing TNF receptor. FEBS Lett 1998, 431:351-356.
50. Nikolaev A., McLaughlin T., O'Leary D.D., Tessier-Lavigne M. APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. Nature 2009, 457:981-989.
51. Klima M., Zajedova J., Doubravska L., Andera L. Functional analysis of the posttranslational modifications of the death receptor 6. Biochim Biophys Acta 2009, 1793:1579-1587.
52. Mosser D.M., Zhang X. Interleukin-10: new perspectives on an old cytokine. Immunol Rev 2008, 226:205-218.
53. Sahoo A., Im S.H. Interleukin and interleukin receptor diversity: role of alternative splicing. Int Rev Immunol 2010, 29:77-109.
54. Wang X., Lupardus P., Laporte S.L., Garcia K.C. Structural biology of shared cytokine receptors. Annu Rev Immunol 2009, 27:29-60.
55. Budagian V., Bulanova E., Paus R., Bulfone-Paus S. IL-15/IL-15 receptor biology: a guided tour through an expanding universe. Cytokine Growth Factor Rev 2006, 17:259-280.
56. Waldmann T.A. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol 2006, 6:595-601.
57. Dubois S., Mariner J., Waldmann T.A., Tagaya Y. IL-15Rα recycles and presents IL-15 In trans to neighboring cells. Immunity 2002, 17:537-547.
58. Ku C.C., Murakami M., Sakamoto A., Kappler J., Marrack P. Control of homeostasis of CD8+ memory T cells by opposing cytokines. Science 2000, 288:675-678.
59. McInnes I.B., Leung B.P., Sturrock R.D., Field M., Liew F.Y. Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor-alpha production in rheumatoid arthritis. Nat Med 1997, 3:189-195.
60. Smith X.G., Bolton E.M., Ruchatz H., Wei X., Liew F.Y., Bradley J.A. Selective blockade of IL-15 by soluble IL-15 receptor α-chain enhances cardiac allograft survival. J Immunol 2000, 165:3444-3450.
61. Mehta D.S., Wurster A.L., Grusby M.J. Biology of IL-21 and the IL-21 receptor. Immunol Rev 2004, 202:84-95.
62. Konforte D., Simard N., Paige C.J. IL-21: an executor of B cell fate. J Immunol 2009, 182:1781-1787.
63. King C., Tangye S.G., Mackay C.R. T follicular helper (TFH) cells in normal and dysregulated immune responses. Annu Rev Immunol 2008, 26:741-766.
64. Avery D.T., Deenick E.K., Ma C.S., Suryani S., Simpson N., Chew G.Y., et al. B cell-intrinsic signaling through IL-21 receptor and STAT3 is required for establishing long-lived antibody responses in humans. J Exp Med 2010, 207:155-171.
65. Ozaki K., Spolski R., Feng C.G., Qi C.F., Cheng J., Sher A., et al. A critical role for IL-21 in regulating immunoglobulin production. Science 2002, 298:1630-1634.
66. Herber D., Brown T.P., Liang S., Young D.A., Collins M., Dunussi-Joannopoulos K. IL-21 has a pathogenic role in a lupus-prone mouse model and its blockade with IL-21R.Fc reduces disease progression. J Immunol 2007, 178:3822-3830.
67. Moore K.W., de Waal Malefyt R., Coffman R.L., O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001, 19:683-765.
68. Williams L.M., Ricchetti G., Sarma U., Smallie T., Foxwell B.M. Interleukin-10 suppression of myeloid cell activation - a continuing puzzle. Immunology 2004, 113:281-292.
69. Pestka S., Krause C.D., Sarkar D., Walter M.R., Shi Y., Fisher P.B. Interleukin-10 and related cytokines and receptors. Annu Rev Immunol 2004, 22:929-979.
70. Kaufmann D., Gruener S., Braun F., Stark M., Griesser J., Hoffmeyer S., et al. EVI2B, a gene lying in an intron of the neurofibromatosis type 1 (NF1) gene, is as the NF1 gene involved in differentiation of melanocytes and keratinocytes and is overexpressed in cells derived from NF1 neurofibromas. DNA Cell Biol 1999, 18:345-356.
71. Morgan M.R., Humphries M.J., Bass M.D. Synergistic control of cell adhesion by integrins and syndecans. Nat Rev Mol Cell Biol 2007, 8:957-969.
72. Essner J.J., Chen E., Ekker S.C. Syndecan-2. Int J Biochem Cell Biol 2006, 38:152-156.
73. Bischof D., Elsawa S.F., Mantchev G., Yoon J., Michels G.E., Nilson A., et al. Selective activation of TACI by syndecan-2. Blood 2006, 107:3235-3242.
74. Yayon A., Klagsbrun M., Esko J.D., Leder P., Ornitz D.M. Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell 1991, 64:841-848.
75. Modrowski D., Basle M., Lomri A., Marie P.J. Syndecan-2 is involved in the mitogenic activity and signaling of granulocyte-macrophage colony-stimulating factor in osteoblasts. J Biol Chem 2000, 275:9178-9185.
76. Chen L., Klass C., Woods A. Syndecan-2 regulates transforming growth factor-β signaling. J Biol Chem 2004, 279:15715-15718.
77. Choi Y., Kim H., Chung H., Hwang J.S., Shin J.A., Han I.O., et al. Syndecan-2 regulates cell migration in colon cancer cells through Tiam1-mediated Rac activation. Biochem Biophys Res Commun 2010, 391:921-925.
78. Lee J.H., Park H., Chung H., Choi S., Kim Y., Yoo H., et al. Syndecan-2 regulates the migratory potential of melanoma cells. J Biol Chem 2009, 284:27167-27175.
79. Teixe T., Nieto-Blanco P., Vilella R., Engel P., Reina M., Espel E. Syndecan-2 and -4 expressed on activated primary human CD4+ lymphocytes can regulate T cell activation. Mol Immunol 2008, 45:2905-2919.
80. Clasper S., Vekemans S., Fiore M., Plebanski M., Wordsworth P., David G., et al. Inducible expression of the cell surface heparan sulfate proteoglycan syndecan-2 (fibroglycan) on human activated macrophages can regulate fibroblast growth factor action. J Biol Chem 1999, 274:24113-24123.
81. Sanchez T., Hla T. Structural and functional characteristics of S1P receptors. J Cell Biochem 2004, 92:913-922.
82. Rivera J., Proia R.L., Olivera A. The alliance of sphingosine-1-phosphate and its receptors in immunity. Nat Rev Immunol 2008, 8:753-763.
83. Matloubian M., Lo C.G., Cinamon G., Lesneski M.J., Xu Y., Brinkmann V., et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 2004, 427:355-360.
84. Wei S.H., Rosen H., Matheu M.P., Sanna M.G., Wang S.K., Jo E., et al. Sphingosine 1-phosphate type 1 receptor agonism inhibits transendothelial migration of medullary T cells to lymphatic sinuses. Nat Immunol 2005, 6:1228-1235.
85. Townsend M.J., Monroe J.G., Chan A.C. B-cell targeted therapies in human autoimmune diseases: an updated perspective. Immunol Rev 2010, 237:264-283.